1. Pink Sheet
  2. >>Regulatory Trackers
  3. >>US FDA Performance Tracker

Naloxone Sponsor Steps In Pricing Hole Disputing FDA's Cost Estimates

 
• By Derrick Gingery

While arguing that US FDA overestimated inflation and fill rates when calculating annual cost of co-prescribing naloxone with opioids, Adapt Pharma opened door to pricing pledge questions that the Narcan sponsor could not answer.

Drug costs_1B_546120055_1200.jpg

Naloxone manufacturers strongly disputed the US FDA's estimate of cost increases associated with co-prescribing the rescue medication with an opioid as vastly overstated, but could not diffuse advisory committee concerns.

The agency also lured Adapt Pharma Ltd./Emergent BioSolutions Inc

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers